The British HIV Association national audit on the management of subjects co-infected with HIV and hepatitis B/C

[Guest guest]

http://ijsa.rsmjournals.com/cgi/content/abstract/22/3/173

Int J STD AIDS 2011;22:173-176

doi:10.1258/ijsa.2010.010380

© 2011 Royal Society of Medicine Press

Audit reports

The British HIV Association national audit on the management of subjects

co-infected with HIV and hepatitis B/C

L Garvey MRCP MBChB * , H Curtis MA PhD , G Brook MD FRCP for the BHIVA Audit

and Standards Sub-Committee

* Imperial College London; British HIV Association; Clements Clinic,

Central Middlesex Hospital, London, UK

Correspondence to: L Garvey, Clinical Trials Centre, Winston Churchill Wing, St

's Hospital, London W2 1NY, UK Email: l.garvey@...

The aim of this work was to survey current service provision and adherence to

the British HIV Association (BHIVA) guidelines for the management of HIV and

hepatitis B/C co-infected patients in the UK. Sites were invited to complete a

survey of local care arrangements for co-infected patients. A case-note audit of

all co-infected attendees during a six-month period in 2009 was performed. Data

including demographics, clinical parameters, hepatitis disease status,

antiretroviral and hepatitis B/C therapy were collected. Using BHIVA guidelines

as audit standards, the proportion of sites and subjects meeting each standard

was calculated. One-hundred and forty sites (75%) responded and data from 973

eligible co-infected patients were submitted. Approximately a third of sites

reported not re-checking hepatitis serology or vaccination titres annually. Of

all co-infected patients, 122 (13%) were neither vaccinated nor immune to

hepatitis A and 26 (5%) of patients with hepatitis C were neither vaccinated nor

naturally immune to hepatitis B. Of HBsAg-positive subjects, 25 (6%) were

receiving lamivudine as the sole drug with antihepatitis B activity. In the UK,

the management of HIV and hepatitis B/C co-infection remains highly variable.

Optimizing the care of this high-risk patient group is a priority.

[Guest guest]

http://ijsa.rsmjournals.com/cgi/content/abstract/22/3/173

Int J STD AIDS 2011;22:173-176

doi:10.1258/ijsa.2010.010380

© 2011 Royal Society of Medicine Press

Audit reports

The British HIV Association national audit on the management of subjects

co-infected with HIV and hepatitis B/C

L Garvey MRCP MBChB * , H Curtis MA PhD , G Brook MD FRCP for the BHIVA Audit

and Standards Sub-Committee

* Imperial College London; British HIV Association; Clements Clinic,

Central Middlesex Hospital, London, UK

Correspondence to: L Garvey, Clinical Trials Centre, Winston Churchill Wing, St

's Hospital, London W2 1NY, UK Email: l.garvey@...

The aim of this work was to survey current service provision and adherence to

the British HIV Association (BHIVA) guidelines for the management of HIV and

hepatitis B/C co-infected patients in the UK. Sites were invited to complete a

survey of local care arrangements for co-infected patients. A case-note audit of

all co-infected attendees during a six-month period in 2009 was performed. Data

including demographics, clinical parameters, hepatitis disease status,

antiretroviral and hepatitis B/C therapy were collected. Using BHIVA guidelines

as audit standards, the proportion of sites and subjects meeting each standard

was calculated. One-hundred and forty sites (75%) responded and data from 973

eligible co-infected patients were submitted. Approximately a third of sites

reported not re-checking hepatitis serology or vaccination titres annually. Of

all co-infected patients, 122 (13%) were neither vaccinated nor immune to

hepatitis A and 26 (5%) of patients with hepatitis C were neither vaccinated nor

naturally immune to hepatitis B. Of HBsAg-positive subjects, 25 (6%) were

receiving lamivudine as the sole drug with antihepatitis B activity. In the UK,

the management of HIV and hepatitis B/C co-infection remains highly variable.

Optimizing the care of this high-risk patient group is a priority.